DSpace at RU >
University Library >
Academic bibliography >
|Title: ||Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas|
|Author(s): ||Muris, J.J.|
Bladergroen, B.A. (175126542)
MacKenzie, M.A. (153072164)
Siegenbeek van Heukelom, L.H.
Ossenkoppele, G.J. (074983709)
|Publication year: ||2004|
|Document type: ||Article / Letter to editor|
|Volume: ||vol. 18|
|Issue: ||iss. 3|
|Start page: ||p. 589|
|End page: ||p. 596|
|Abstract: ||Clinical outcome in diffuse large B-cell lymphoma (DLBCL) remains unpredictable, despite the identification of clinical prognostic parameters. Here, we investigated in pretreatment biopsies of 70 patients with DLBCL whether numbers of activated cytotoxic T-lymphocytes (CTLs), as determined by the percentage of CD3-positive lymphocytes with granzyme B (GrB) expression, have similar prognostic value as found earlier in Hodgkin's lymphoma and anaplastic large-cell lymphoma and whether loss of major histocompatibility complex (MHC)-I molecules or expression of the GrB antagonist protease inhibitor 9 (PI9) may explain immune escape from CTL-mediated cell death. Independent of the International Prognostic Index (IPI), the presence of >/=15% activated CTLs was strongly associated with failure to reach complete remission, with a poor progression-free and overall survival time. Downregulation of MHC-I light- and/or heavy-chain expression was found in 41% of interpretable cases and in 19 of 56 interpretable cases PI9 expression was detected. We conclude that a high percentage of activated CTLs is a strong, IPI independent, indicator for an unfavorable clinical outcome in patients with primary nodal DLBCL.
Although in part of DLBCL expression of PI9 and loss of MHC-I expression was found, providing a possible immune-escape mechanism in these cases, no correlation with clinical outcome was found.Leukemia advance online publication, 18 December 2003; doi:10.1038/sj.leu.2403240|
|Subject: ||UMCN 1.3: Tumor microenvironment|
UMCN 1.4: Immunotherapy, gene therapy and transplantation
UMCN 4.3: Tissue engineering and reconstructive surgery
|Organization: ||UMCN Extern|
|Appears in Collections:||Academic bibliography|
Please use this identifier to cite or link to this item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.